Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitneprotafib (JAB-3312) in advanced solid tumors
NCT04121286Phase 1Completed
- Sponsor
- Allist Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sitneprotafib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 4 more, sponsored by Allist Pharmaceuticals. Primary endpoints: Number of participants with dose limiting toxicities at 2 years and Recommended Phase 2 Dose at 2 years. Started Jul 2020; status: completed.
02
Drugs
sitneprotafib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04121286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121286.